Avirup Guha: 6 Posters Spanning Cardio-Oncology – Oncodaily

AI News Q&A (Free Content)

Q1: What are the key findings from Avirup Guha's recent presentations at the American Society of Clinical Oncology (ASCO) regarding cardio-oncology?

A1: Avirup Guha, along with his colleague Harikrishnan Hyma Kunhiraman, presented six posters at the ASCO focusing on cardio-oncology and multi-omics in prostate cancer. The key findings highlighted the importance of community education in reducing cardiovascular and overall mortality in prostate cancer patients, and the need for simple, fast, lab-independent cardiovascular risk assessment tools that fit seamlessly into clinical workflows. This research emphasizes the potential of geographically targeted survivorship care.

Q2: How does the recent study on clonal hematopoiesis and cardiomyopathy in cardio-oncology patients utilize deep learning?

A2: The study developed a novel deep learning framework to detect clonal hematopoiesis of indeterminate potential (CHIP) and predict future cardiomyopathy in cardio-oncology patients using cardiac magnetic resonance imaging. The model showed promising results with an AUC of 0.71 for CHIP detection and 0.87 for predicting cardiomyopathy, suggesting its potential as a non-invasive tool for risk stratification in cardiovascular care.

Q3: What advancements have been made in using electrocardiograms (ECG) for diagnosing neoplasms, as discussed in recent research?

A3: Recent research has demonstrated the potential of using ECG data combined with machine learning to diagnose neoplasms by identifying cardiovascular changes linked to neoplastic presence. The study achieved high diagnostic accuracy and showed that this method is cost-effective and scalable for resource-limited settings, providing a non-invasive alternative to traditional diagnostic methods.

Q4: What are the implications of recent cardio-oncology research on the management of cancer survivors?

A4: Recent research in cardio-oncology highlights the rising importance of cardiovascular disease (CVD) as a competing cause of morbidity among cancer survivors. Studies emphasize the need for integrated cardio-hematology care to manage the multifactorial pathways of treatment-related cardiovascular toxicity. These findings call for further research to develop optimal care strategies for cancer survivors with cardiovascular risks.

Q5: How is artificial intelligence being integrated into precision medicine in the field of cardio-oncology?

A5: Artificial intelligence (AI) is increasingly being used to enhance precision medicine in cardio-oncology by improving the accuracy of cardiovascular risk assessments and tailoring treatment plans to individual patients. AI tools are being developed to analyze large datasets, predict treatment outcomes, and identify potential side effects of cancer therapies, thereby supporting personalized care strategies.

Q6: What are some of the latest clinical trials in cardio-oncology, and what do they aim to achieve?

A6: Current clinical trials in cardio-oncology aim to understand and mitigate the cardiovascular risks associated with cancer treatments. For instance, trials are investigating the effects of anti-cancer therapies on the heart and developing strategies to prevent severe side effects like myocarditis. These trials are crucial for refining treatment protocols and improving long-term outcomes for cancer survivors.

Q7: What role does community education play in improving cardiovascular outcomes for cancer patients, according to Avirup Guha's research?

A7: Avirup Guha's research underscores the role of community education as a potentially actionable factor in improving cardiovascular outcomes for cancer patients. His findings from ASCO indicate that men living in lower-education counties experience higher cardiovascular and overall mortality. This suggests that targeted educational interventions could be crucial in enhancing survivorship care and reducing health disparities.

References:

• Assessment of Clonal Hematopoiesis of Indeterminate Potential and Future Cardiomyopathy from Cardiac Magnetic Resonance Imaging using Deep Learning in a Cardio-oncology Population
• Explainable machine learning for neoplasms diagnosis via electrocardiograms: an externally validated study
• Myeloid Neoplasms Meet Cardiovascular Epidemiology: A Call for Integrated Cardio-hematology Care.", "Artificial Intelligence to Enhance Precision Medicine in Cardio-Oncology: A Scientific Statement From the American Heart Association.